Edition:
United Kingdom

Takashi Umekawa

Novartis gets approval to sell Kymriah in Japan for $306,000

15 May 2019

TOKYO A Japanese government panel approved on Wednesday a price of 33.5 million yen ($305,800) for Novartis' cancer treatment Kymriah, allowing the Swiss drugmaker to press ahead with a campaign to kick-start sluggish sales of the treatment.

Japan's Takeda forecasts surprise annual loss on Shire-related costs

14 May 2019

TOKYO Takeda Pharmaceutical Co forecast an unexpected operating loss for the current year due to costs associated with the $59 billion purchase of Shire Plc, providing the first set of financial results of the combined firm.

Novartis buys dry eye drug from Takeda for up to $5.3 billion

09 May 2019

TOKYO/ZURICH Novartis is buying dry-eye drug Xiidra from Takeda Pharmaceutical Co for up to $5.3 billion as the Swiss drugmaker refreshes its ophthalmic medicines portfolio with a potential blockbuster.

Japan's Sharp to miss mid-term target, laments impact of Sino-U.S. trade

09 May 2019

TOKYO Japan's Sharp Corp, an Apple Inc supplier, said on Thursday it would not meet its mid-term profit target in the current fiscal year after a shift in focus, and that a U.S.-China trade war is impacting its relationship with clients.

Japanese drugmaker Shionogi sees record profit on royalty income

09 May 2019

TOKYO Japanese drugmaker Shionogi & Co Ltd forecast a 6.1 percent jump in full-year operating profit to what would be its fifth straight record high, underpinned by strong royalty income from its HIV drugs.

Nomura suffers first annual loss in a decade, scraps directors' bonuses

25 Apr 2019

TOKYO Japan's Nomura Holdings Inc reported an annual loss for the first time in a decade and said it would not pay directors' bonuses, amid rising pressure to right its wholesale business and drastically pare back costs.

Despite headwind, Japan's Nomura says intent on going it alone

19 Apr 2019

TOKYO Japan's Nomura Holdings has no plan to follow the lead of Wall Street rivals and seek a tie-up with a commercial lender, its chief executive told Reuters, pledging to stay independent even as the investment bank faces its first annual loss in a decade.

RPT-UPDATE 3-Japan's Nomura axeing jobs and bank branches to cut costs by $1 bln

04 Apr 2019

* Plans about 100 job cuts in London as part of trading overhaul

UPDATE 3-Japan's Nomura axeing jobs and bank branches to cut costs by $1 bln

04 Apr 2019

* Plans about 100 job cuts in London as part of trading overhaul

World News